JP7649283B2 - 新規複素環化合物 - Google Patents

新規複素環化合物 Download PDF

Info

Publication number
JP7649283B2
JP7649283B2 JP2022500908A JP2022500908A JP7649283B2 JP 7649283 B2 JP7649283 B2 JP 7649283B2 JP 2022500908 A JP2022500908 A JP 2022500908A JP 2022500908 A JP2022500908 A JP 2022500908A JP 7649283 B2 JP7649283 B2 JP 7649283B2
Authority
JP
Japan
Prior art keywords
chloro
phenyl
oxazin
methanone
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022500908A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022539604A (ja
JP2022539604A5 (https=
Inventor
グレター，ウーヴェ
ホルンスペルガー，ブノワ
クーン，ベルント
リヒター，ハンス
オハラ，フィオン
クロール，カールステン
レッジアーニ，フローレ
ビーダーマン，モーリス
コサール，ミロスラフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67220669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7649283(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2022539604A publication Critical patent/JP2022539604A/ja
Publication of JP2022539604A5 publication Critical patent/JP2022539604A5/ja
Application granted granted Critical
Publication of JP7649283B2 publication Critical patent/JP7649283B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022500908A 2019-07-09 2020-07-07 新規複素環化合物 Active JP7649283B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19185088.2 2019-07-09
EP19185088 2019-07-09
PCT/EP2020/069074 WO2021005034A1 (en) 2019-07-09 2020-07-07 New heterocyclic compounds

Publications (3)

Publication Number Publication Date
JP2022539604A JP2022539604A (ja) 2022-09-12
JP2022539604A5 JP2022539604A5 (https=) 2025-02-07
JP7649283B2 true JP7649283B2 (ja) 2025-03-19

Family

ID=67220669

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022500908A Active JP7649283B2 (ja) 2019-07-09 2020-07-07 新規複素環化合物

Country Status (19)

Country Link
US (1) US20220242876A1 (https=)
EP (1) EP3997096B1 (https=)
JP (1) JP7649283B2 (https=)
KR (1) KR20220034104A (https=)
CN (1) CN114096545A (https=)
AR (1) AR119376A1 (https=)
AU (1) AU2020311584A1 (https=)
BR (1) BR112021026899A2 (https=)
CA (1) CA3145338A1 (https=)
CL (1) CL2022000019A1 (https=)
CO (1) CO2022000186A2 (https=)
CR (1) CR20220004A (https=)
IL (1) IL288987A (https=)
MX (1) MX2022000243A (https=)
PE (1) PE20220515A1 (https=)
PH (1) PH12021553249A1 (https=)
TW (1) TW202116781A (https=)
WO (1) WO2021005034A1 (https=)
ZA (1) ZA202110352B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019134985A1 (en) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
PE20211089A1 (es) 2018-08-13 2021-06-14 Hoffmann La Roche Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa
WO2020104494A1 (en) 2018-11-22 2020-05-28 F. Hoffmann-La Roche Ag New heterocyclic compounds
CN114269755A (zh) 2019-09-12 2022-04-01 豪夫迈·罗氏有限公司 作为magl抑制剂的4,4a,5,7,8,8a-六吡啶并[4,3-b][1,4]噁嗪-3-酮化合物
CA3190277A1 (en) 2020-09-03 2022-03-10 Joerg Benz Heterocyclic compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014521751A (ja) 2011-08-19 2014-08-28 メルク・シャープ・アンド・ドーム・コーポレーション 腎髄質外層カリウムチャンネルの阻害薬
WO2017087863A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
WO2019046318A1 (en) 2017-08-29 2019-03-07 Abide Therapeutics, Inc. SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF
JP2021510158A (ja) 2018-01-08 2021-04-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｍａｇｌ阻害剤としてのオクタヒドロピリド［１，２−アルファ］ピラジン
JP2022540367A (ja) 2019-07-03 2022-09-15 エフ．ホフマン－ラ ロシュ アーゲー 複素環モノアシルグリセロールリパーゼ（ｍａｇｌ）阻害剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9573961B2 (en) 2012-12-19 2017-02-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP3571202B1 (en) * 2017-01-23 2021-06-30 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
JOP20190267A1 (ar) * 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014521751A (ja) 2011-08-19 2014-08-28 メルク・シャープ・アンド・ドーム・コーポレーション 腎髄質外層カリウムチャンネルの阻害薬
WO2017087863A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
WO2019046318A1 (en) 2017-08-29 2019-03-07 Abide Therapeutics, Inc. SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF
JP2021510158A (ja) 2018-01-08 2021-04-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｍａｇｌ阻害剤としてのオクタヒドロピリド［１，２−アルファ］ピラジン
JP2022540367A (ja) 2019-07-03 2022-09-15 エフ．ホフマン－ラ ロシュ アーゲー 複素環モノアシルグリセロールリパーゼ（ｍａｇｌ）阻害剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REGISTRY(STN)[online]，［検索日 2024.3.13］CAS登録番号 2307419-63-0, 2307414-36-2, 2307410-83-7, 2307406-57-9, 2307399-63-7, 2307399-15-9, 2307398-78-1, 2307396-97-8, 2307394-14-3, 2307377-28-0, 2307376-61-8, 2307370-64-3, 2307366-05-6, 2307363-01-3, 2307362-05-4, 2307356-33-6, 2307354-31-8, 2307354-25-0, 2307353-85-9, 2307347-32-4(いずれも ED: 2019.05.12)

Also Published As

Publication number Publication date
PH12021553249A1 (en) 2023-02-27
BR112021026899A2 (pt) 2022-05-10
EP3997096A1 (en) 2022-05-18
ZA202110352B (en) 2022-08-31
TW202116781A (zh) 2021-05-01
CR20220004A (es) 2022-01-31
WO2021005034A1 (en) 2021-01-14
EP3997096C0 (en) 2024-08-28
CL2022000019A1 (es) 2022-10-21
IL288987A (en) 2022-02-01
CO2022000186A2 (es) 2022-01-17
PE20220515A1 (es) 2022-04-07
AR119376A1 (es) 2021-12-15
EP3997096B1 (en) 2024-08-28
KR20220034104A (ko) 2022-03-17
MX2022000243A (es) 2022-02-03
JP2022539604A (ja) 2022-09-12
US20220242876A1 (en) 2022-08-04
AU2020311584A1 (en) 2022-01-20
CA3145338A1 (en) 2021-01-14
CN114096545A (zh) 2022-02-25

Similar Documents

Publication Publication Date Title
JP7649283B2 (ja) 新規複素環化合物
JP7609854B2 (ja) Ｍａｇｌ阻害剤としての４，４ａ，５，７，８，８ａ－ヘキサピリド［４，３－ｂ］［１，４］オキサジン－３－オン化合物
JP7707073B2 (ja) モノアシルグリセロールリパーゼ（ｍａｇｌ）の阻害剤としての複素環式化合物
TWI818967B (zh) 新穎雜環化合物
TWI812770B (zh) 新穎雜環化合物
JP2021533093A (ja) モノアシルグリセロールリパーゼ阻害剤としての新規複素環化合物
JP7669299B2 (ja) 複素環モノアシルグリセロールリパーゼ（ｍａｇｌ）阻害剤
JP2022549446A (ja) 新規複素環モノアシルグリセロールリパーゼ（ｍａｇｌ）阻害剤
JP2024521618A (ja) 複素環式化合物
JP2024540874A (ja) 複素環式化合物
JP2025503438A (ja) モノアシルグリセロールリパーゼ阻害剤として有用な二環式複素環化合物
HK40068386A (en) New heterocyclic compounds
WO2025068347A1 (en) New heterocyclic compounds
HK40065118A (en) New heterocyclic monoacylglycerol lipase (magl) inhibitors
CN118103374A (zh) 杂环化合物
HK40035599A (en) Oxazine monoacylglycerol lipase (magl) inhibitors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230330

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250307

R150 Certificate of patent or registration of utility model

Ref document number: 7649283

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150